<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548194</url>
  </required_header>
  <id_info>
    <org_study_id>BNC210.008</org_study_id>
    <nct_id>NCT03548194</nct_id>
  </id_info>
  <brief_title>A Study of BNC210 in Elderly Patients With Agitation</brief_title>
  <official_title>A Phase II Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BNC210 in Hospitalised Elderly Patients With Agitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionomics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionomics Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II randomised, double-blind, placebo-controlled study assessing the effects
      of BNC210 on agitation in hospitalised elderly patients as measured by the Pittsburgh
      Agitation Scale (PAS). Safety and tolerability of BNC210 will also be assessed.

      The secondary objectives of the study include evaluation of the effects of BNC210 on global
      function in patients with agitation as assessed by the Clinical Global Impression Scale
      (CGI-S/I).

      Participants will receive 5 days of blinded treatment followed by 2 days of follow up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">April 24, 2019</completion_date>
  <primary_completion_date type="Actual">April 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in agitation, as measured by the Pittsburgh Agitation Scale (PAS).</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in global function, as measured by the Clinical Global Impression Scale - Severity and Improvement (CGI-S/I)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants reaching the &quot;Non-Agitated&quot; state</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first reach a &quot;Non-Agitated&quot; state.</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Agitation in the Elderly</condition>
  <arm_group>
    <arm_group_label>BNC210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally b.i.d. for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered orally b.i.d. for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BNC210</intervention_name>
    <description>BNC210 300 mg b.i.d</description>
    <arm_group_label>BNC210</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo b.i.d.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female elderly patient admitted to hospital and under the care of a specialist
             Geriatrician

          -  Determined to have agitation requiring intervention in addition to standard of care
             behavioural management, as assessed by the Investigator or delegate, after at least 24
             hours following admission to hospital.

        Key Exclusion Criteria:

          -  Severe Alzheimer's Dementia (stage 7) as assessed by the Functional Assessment Staging
             Test (FAST).

          -  Diagnosed with Severe Parkinson's Disease.

          -  Premorbid psychotic illness as assessed by the Investigator.

          -  Evidence of severe organ dysfunction

          -  Confirmed metastatic malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modbury Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

